Skip to main content
Clinical Trials/NCT06311435
NCT06311435
Recruiting
Not Applicable

Utilizing Novel Blood RNA Biomarkers as a Diagnostic Tool in the Identification of Long COVID-19

MaxWell Clinic, PLC2 sites in 1 country224 target enrollmentMarch 15, 2024
ConditionsLong COVID

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Long COVID
Sponsor
MaxWell Clinic, PLC
Enrollment
224
Locations
2
Primary Endpoint
Develop algorithm to classify RNA sequences to identify long COVID
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

The Primary objective of this study is to determine, using unblinded samples, if it is possible to develop an algorithm for the classification of specific blood RNA from patients with long COVID together and separately from the apparent health normal controls and other medical conditions that share the signs and symptoms of long COVID.

Detailed Description

Participants will be screened and provide two blood samples28 (+/- 2) days apart. Based on the participants survey results they will be placed into one of fourteen groups that reflect the type of Long COVID the patient is experiencing. Samples will be shipped to the sponsor who will develop an AI process to validate the type of Long COVID and assess its severity. The long term goal is to develop a reliable test to identify the presence of Long COVID and its severity.

Registry
clinicaltrials.gov
Start Date
March 15, 2024
End Date
March 15, 2026
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
MaxWell Clinic, PLC
Responsible Party
Principal Investigator
Principal Investigator

Cale T Queen

Executive Director

MaxWell Clinic, PLC

Eligibility Criteria

Inclusion Criteria

  • Mentally capable of understanding and completing informed consent for the study.
  • Precipitants with a lab verified diagnosis of SARS-CoV-2 or clinician note/record that an appropriate rapid test for SARS-CoV-2 was positive.
  • To qualify for long COVID group participants will need to have new, persistent symptoms related to SARS-CoV-2 infection. iv. No one under the age of 18.

Exclusion Criteria

  • Subject is unable to provide informed consent.
  • Primary Investigator or Sub-Investigator determines the participant's ongoing medical complaints that began after 1 November 2019 are not related to SARS-COV-2 but another disease process.

Outcomes

Primary Outcomes

Develop algorithm to classify RNA sequences to identify long COVID

Time Frame: 30 days

The Primary objective of this study is to determine, using unblinded samples, if it is possible to develop an algorithm for the classification of specific blood RNA from patients with long COVID together and separately from the apparent health normal controls and other medical conditions that share the signs and symptoms of long COVID

Secondary Outcomes

  • Develop algorithm to subclassify specific RNA sequences to subclassify types of Long COVID(30 Days)

Study Sites (2)

Loading locations...

Similar Trials